Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022006392 - NOVEL PHARMACEUTICAL COMPOSITIONS

Publication Number WO/2022/006392
Publication Date 06.01.2022
International Application No. PCT/US2021/040084
International Filing Date 01.07.2021
IPC
A61K 31/18 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
18Sulfonamides
A61K 31/4355 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4355the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
C07C 311/39 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
311Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
37having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
38having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
39having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
Applicants
  • NEUROPRO THERAPEUTICS, INC. [US]/[US]
Inventors
  • HOCHMAN, Daryl W.
Agents
  • FIX, Amy
  • HASAN, Aisha
Priority Data
63/046,74301.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL PHARMACEUTICAL COMPOSITIONS
(FR) NOUVELLES COMPOSITIONS PHARMACEUTIQUES
Abstract
(EN) The present disclosure relates to novel pharmaceutical compositions for active pharmaceutical ingredients subject to first pass metabolism. More particularly, bumetanide analogs, including bumetanide dibenzylamide, bumetanide diethylamide, and bumetanide morpholinoamide, are demonstrated as susceptible to first pass metabolism, thereby prompting effort toward developing an acceptable pharmaceutical formulation to provide adequate bioavailability.
(FR) La présente divulgation se rapporte à de nouvelles compositions pharmaceutiques pour des principes actifs pharmaceutiques soumis à un métabolisme de premier passage. Plus particulièrement, des analogues du bumétanide, comprenant le dibenzylamide de bumétanide, le diéthylamide de bumétanide et le morpholinoamide de bumétanide, se sont révélés être sensibles à un métabolisme de premier passage, incitant ainsi à l'effort de développement d'une formulation pharmaceutique acceptable pour fournir une biodisponibilité adéquate.
Latest bibliographic data on file with the International Bureau